Clinical Trials
Open
SWOG Clinical Trial Number
LUNGMAP
A MASTER PROTOCOL TO EVALUATE BIOMARKER-DRIVEN THERAPIES AND IMMUNOTHERAPIES IN PREVIOUSLY-TREATED NON-SMALL CELL LUNG CANCER (Lung-MAP Screening Study)
Status Notes
LUNGMAP will open to accrual January 28, 2019, effective 2:00 pm PST.
This is a potential FDA registration study. There will be additional centralized and on-site monitoring conducted in addition to routine audits. Sites must also maintain a study specific Trial Master File for this study (https://swog.org/Visitors/QA/Index.asp).
This is a potential FDA registration study. There will be additional centralized and on-site monitoring conducted in addition to routine audits. Sites must also maintain a study specific Trial Master File for this study (https://swog.org/Visitors/QA/Index.asp).
Research Committee(s)
Lung Cancer
Activated
01-28-2019
Open
SWOG Clinical Trial Number
S1900BDSS
S1900 Biomarker-Driven Sub-Study Version Control Protocol (S1900BDSS VCP)
Status Notes
The LUNGMAP S1900 Biomarker-Driven Sub-Study Version Control Protocol (S1900BDSS) is active effective 1/28/19.
The intent of the S1900BDSS is to allow an individual sub-study to be revised independently of the other sub-studies. The S1900BDSS keeps track of revisions made to various S1900 biomarker-driven sub-studies of LUNGMAP and their component documents over the course of the overarching Lung-MAP study, and lists the version date of each revision.
Sites may use this document to verify the most current version of a LUNGMAP S1900 biomarker-driven sub-study, and may also reference this document for an overview of S1900 sub-study revisions.
The intent of the S1900BDSS is to allow an individual sub-study to be revised independently of the other sub-studies. The S1900BDSS keeps track of revisions made to various S1900 biomarker-driven sub-studies of LUNGMAP and their component documents over the course of the overarching Lung-MAP study, and lists the version date of each revision.
Sites may use this document to verify the most current version of a LUNGMAP S1900 biomarker-driven sub-study, and may also reference this document for an overview of S1900 sub-study revisions.
Research Committee(s)
Lung Cancer
Activated
01-28-2019
Open
Accrual
0%
SWOG Clinical Trial Number
S1815
A phase III randomized trial of gemcitabine, cisplatin, and nab-paclitaxel versus gemcitabine and cisplatin in newly diagnosed, advanced biliary tract cancers
Status Notes
Activation effective Monday, December 3, 2018.
Research Committee(s)
Gastrointestinal Cancer
Activated
12-03-2018
Open
Phase
Accrual
3%
SWOG Clinical Trial Number
S1802
Phase III Randomized Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer
Status Notes
Activated 9/17/18.
Research Committee(s)
Genitourinary Cancer
Other
Symptom Control and Quality of Life
Activated
09-17-2018
Open
Accrual
1%
SWOG Clinical Trial Number
S1706
A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrently with Radiotherapy versus Radiotherapy Alone for Inflammatory Breast Cancer
Status Notes
Activation, Effective 9/12/2018, 2:00 pm CT
Research Committee(s)
Breast Cancer
Activated
09-12-2018
ClinicalTrials.gov Registry Number
NCT03598257
Open
Phase
II
Accrual
0%
SWOG Clinical Trial Number
S1701
A Randomized Phase II trial of Carboplatin-Paclitaxel with or without Ramucirumab in Patients with Unresectable Locally Advanced, Recurrent, or Metastatic Thymic Carcinoma
Status Notes
This study is open to accrual effective 8/9/18.
Research Committee(s)
Lung Cancer
Activated
08-09-2018